NewAmsterdam Pharma and Menarini win EU approval for Ubeslo and Evlarco
NewAmsterdam Pharma Company N.V. and Menarini Group have secured European marketing authorisations for Ubeslo and Evlarco, turning obicetrapib into a commercial-stage cholesterol therapy while leaving PREVAIL to answer the more consequential question of whether its LDL reductions translate into fewer cardiovascular events.